EKF Diagnostics Holdings PLC Director/PDMR Shareholding (2901X)
30 Abril 2021 - 09:52AM
UK Regulatory
TIDMEKF
RNS Number : 2901X
EKF Diagnostics Holdings PLC
30 April 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director Dealing
The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been
informed that on 30 April 2021 Adam Reynolds, Non-Executive
Director, sold a total of 500,000 ordinary shares of 1 pence each
in the Company ("Ordinary Shares") at a price of 73.05 pence per
Ordinary Share.
Following this transaction, Adam Reynold's total direct and
indirect interest in the Group is 1,168,613 Ordinary Shares
representing approximately 0.26% of the Group's total issued share
capital.
The Notification of Dealing Form required in accordance with UK
MAR is set out below.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the USA for a variety of life science
products.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Adam Reynolds
--------------------------------- ------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------- ------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name EKF Diagnostics Holdings plc
--------------------------------- ------------------------------------------
b) LEI 213800DXTF3EAUK1AR05
--------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 each
financial instrument,
type of instrument
Identification code GB0031509804
b) Nature of the transaction Sale of Ordinary Shares
--------------------------------- ------------------------------------------
c) Price(s) and volume(s)
----------------------- --------------
Price(s) (pence) Volume(s)
----------------------- --------------
73.05 500,000
----------------------- --------------
d) Aggregated information
- Aggregated volume N/A - Single Transaction
- Price
e) Date of the transaction 30 April 2021
--------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
--------------------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSGDSISXDGBG
(END) Dow Jones Newswires
April 30, 2021 10:52 ET (14:52 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024